Every filing for G1933S101 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
He Wei-Wu
13D/A
Amendment 15
|
58.8% |
5/18/2026
Event 5/18/2026
|
|
| WEI-WU HE, Ph.D. | 58.8% | ||
| Huiying Memorial Foundation | 3.1% | ||
| Emerging Technology Partners, LLC | 52.0% | ||
| ETP Global Fund L.P. | 3.7% | ||
| Etp Biohealth III Fund, L.P. | 1.5% | ||
| HE Family GRAT | 0.5% | ||
| ETP Global III Fund L.P. | 49.3% | ||
|
He Wei-Wu
13D/A
Amendment 14
|
53.0% |
3/23/2026
Event 3/23/2026
|
|
| WEI-WU HE, Ph.D. | 53.0% | ||
| Huiying Memorial Foundation | 3.1% | ||
| Emerging Technology Partners, LLC | 45.3% | ||
| ETP Global Fund L.P. | 3.7% | ||
| Etp Biohealth III Fund, L.P. | 1.5% | ||
| HE Family GRAT | 0.5% | ||
| ETP Global III Fund L.P. | 42.2% | ||
|
Venrock Healthcare Capital Partners III, L.P.
13G/A
Amendment 1
|
9.2% |
2/17/2026
Event 12/31/2025
|
|
| Venrock Healthcare Capital Partners III, L.P. | 9.2% | ||
| VHCP Co-Investment Holdings III, LLC | 9.2% | ||
| Venrock Healthcare Capital Partners EG, L.P. | 9.2% | ||
| VHCP Management III, LLC | 9.2% | ||
| VHCP Management EG, LLC | 9.2% | ||
| Nimish Shah | 9.2% | ||
| Bong Y. Koh | 9.2% | ||
|
Foresite Capital Fund VI LP
13G/A
Amendment 3
|
0% |
2/13/2026
Event 12/31/2025
|
|
| Foresite Capital Fund VI LP | 0% | ||
| Foresite Capital Management VI LLC | 0% | ||
| James Tananbaum | 0% | ||
|
He Wei-Wu
13D/A
Amendment 13
|
45.4% |
2/10/2026
Event 2/9/2026
|
|
| WEI-WU HE, Ph.D. | 45.4% | ||
| Huiying Memorial Foundation | 3.1% | ||
| Emerging Technology Partners, LLC | 5.3% | ||
| ETP Global Fund L.P. | 3.7% | ||
| Etp Biohealth III Fund, L.P. | 1.5% | ||
| HE Family GRAT | 0.5% | ||
| ETP Global Fund III L.P. | 32.7% | ||
|
He Wei-Wu
13D/A
Amendment 12
|
34.8% |
1/29/2026
Event 1/27/2026
|
|
| WEI-WU HE, Ph.D. | 34.8% | ||
| Huiying Memorial Foundation | 3.1% | ||
| Emerging Technology Partners, LLC | 5.3% | ||
| ETP Global Fund L.P. | 3.7% | ||
| Etp Biohealth III Fund, L.P. | 1.5% | ||
| HE Family GRAT | 0.5% | ||
| ETP Global Fund III L.P. | 19.6% | ||
|
Ho Chi Sing
13D/A
Amendment 7
|
4.8% |
1/20/2026
Event 9/30/2025
|
|
| IDG-Accel China Growth Fund III L.P. | 4.5% | ||
| IDG-Accel China III Investors L.P. | 4.5% | ||
| IDG-Accel China Growth Fund III Associates L.P. | 4.5% | ||
| IDG-Accel China Growth Fund GP III Associates Ltd. | 4.5% | ||
| Ho Chi Sing | 4.5% | ||
| Zhou Quan | 4.8% | ||
|
Sparkle Byte Ltd
13D/A
Amendment 5
|
5.0% |
1/20/2026
Event 9/30/2025
|
|
| Sparkle Byte Ltd | 5.0% | ||
| Snow Moon Ltd | 5.0% | ||
| Tianjin Jingran Management Center (Limited Partnership) | 5.0% | ||
| Beijing Hexie Kangjian Investment Center (Limited Partnership) | 5.0% | ||
| Beijing Hexie Tiancheng Investment Management Center (Limited Partnership) | 5.0% | ||
| He Xie Ai Qi Investment Management (Beijing) Co., Ltd. | 5.0% | ||
| Xizang Hexie Enterprise Management Co., Ltd. | 5.0% | ||
| Zhuhai Hexie Zhiyuan Management Consulting Co., Ltd. | 5.0% | ||
| Jianguang Li | 5.0% | ||
| Dongliang Lin | 5.0% | ||
| Jingbo Wang | 5.0% | ||
| Kuiguang Niu | 5.0% | ||
|
He Wei-Wu
13D/A
Amendment 11
|
19.1% |
1/9/2026
Event 1/9/2026
|
|
| WEI-WU HE, Ph.D. | 19.1% | ||
| Huiying Memorial Foundation | 3.1% | ||
| Emerging Technology Partners, LLC | 5.3% | ||
| ETP Global Fund L.P. | 3.7% | ||
| Etp Biohealth III Fund, L.P. | 1.5% | ||
| HE Family GRAT | 0.5% | ||
|
He Wei-Wu
13D/A
Amendment 10
|
19.1% |
12/18/2025
Event 12/18/2025
|
|
| WEI-WU HE, Ph.D. | 19.1% | ||
| Huiying Memorial Foundation | 3.1% | ||
| Emerging Technology Partners, LLC | 5.3% | ||
| ETP Global Fund L.P. | 3.7% | ||
| Etp Biohealth III Fund, L.P. | 1.5% | ||
| HE Family GRAT | 0.5% | ||
|
Panacea Innovation Ltd
13D/A
Amendment 1
|
22.5% |
12/17/2025
Event 12/16/2025
|
|
| Panacea Venture Healthcare Fund II, L.P. | 22.0% | ||
| Panacea Venture Healthcare Fund II GP Company, Ltd. | 22.0% | ||
| Panacea Innovation Limited | 22.0% | ||
| James Huang | 22.5% | ||
| Chen Zhenfeng M 13G | 11.0% |
11/26/2025
Event 9/30/2025
|
|
|
Foresite Capital Fund VI LP
13G/A
Amendment 2
|
6.3% |
11/14/2025
Event 9/30/2025
|
|
| Foresite Capital Fund VI LP | 6.3% | ||
| Foresite Capital Management VI LLC | 6.3% | ||
| James Tananbaum | 6.3% | ||
|
Panacea Innovation Ltd
13D
|
19.9% |
9/26/2025
Event 9/26/2025
|
|
| Panacea Venture Healthcare Fund II, L.P. | 19.4% | ||
| Panacea Venture Healthcare Fund II GP Company, Ltd. | 19.4% | ||
| Panacea Innovation Limited | 19.4% | ||
| James Huang | 19.9% | ||
|
Foresite Capital Fund VI LP
13G/A
Amendment 1
|
5.1% |
8/12/2025
Event 6/30/2025
|
|
| Foresite Capital Fund VI, L.P. | 5.1% | ||
| Foresite Capital Management VI, LLC | 5.1% | ||
| James Tananbaum | 5.1% | ||
|
James Huang
13G/A
Amendment 6
|
13.8% |
7/23/2025
Event 6/30/2025
|
|
| Panacea Venture Healthcare Fund II, L.P. | 13.2% | ||
| Panacea Venture Healthcare Fund II GP Company, Ltd. | 13.2% | ||
| Panacea Innovation Limited | 13.2% | ||
| James Huang | 13.8% | ||
|
He Wei-Wu
13D/A
Amendment 9
|
23.8% |
6/20/2025
Event 6/16/2025
|
|
| WEI-WU HE, Ph.D. | 23.8% | ||
| Huiying Memorial Foundation | 2.6% | ||
| Emerging Technology Partners, LLC | 7.1% | ||
| ETP Global Fund L.P. | 4.9% | ||
| Etp Biohealth III Fund , L.P. | 1.9% | ||
| HE Family GRAT | 0.6% | ||
|
Ho Chi Sing
13D/A
Amendment 6
|
6.4% |
2/3/2025
Event 12/30/2024
|
|
| IDG-Accel China Growth Fund III L.P. | 5.9% | ||
| IDG-Accel China III Investors L.P. | 5.9% | ||
| IDG-Accel China Growth Fund III Associates L.P. | 5.9% | ||
| IDG-Accel China Growth Fund GP III Associates Ltd. | 5.9% | ||
| Ho Chi Sing | 5.9% | ||
| Quan Zhou | 6.4% |
| Period | Filers | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 1 | 100 | $11 |
| 2026 Q2 | 1 | 100 | $17 |
| 2026 Q1 | 1 | 228 | $25 |
| 2025 Q4 | 16 | 1.25 M | $1.06M |
| 2025 Q3 | 22 | 2.61 M | $4.33M |
| 2025 Q2 | 25 | 2.26 M | $2.66M |
| 2025 Q1 | 24 | 2.74 M | $5.93M |
| 2024 Q4 | 23 | 2.66 M | $7.52M |
| 2024 Q3 | 21 | 1.32 M | $8.14M |
| 2024 Q2 | 24 | 354 k | $1.94M |
| 2024 Q1 | 22 | 255 k | $920k |
| 2023 Q4 | 19 | 277 k | $1.99M |
| 2023 Q3 | 20 | 345 k | $883k |
| 2023 Q2 | 20 | 450 k | $1.12M |
| 2023 Q1 | 21 | 930 k | $2.15M |
| 2022 Q4 | 1 | 100 | $179 |